| Literature DB >> 23841098 |
Laila Berg1, Trine Aakvik Strand, Svein Valla, Trygve Brautaset.
Abstract
Microbial promoters are important targets both for understanding the global gene expression and developing genetic tools for heterologous expression of proteins and complex biosynthetic pathways. Previously, we have developed and used combinatorial mutagenesis methods to analyse and improve bacterial expression systems. Here, we present for the first time an analogous strategy for yeast. Our model promoter is the strong and inducible P AOX1 promoter in methylotrophic Pichia pastoris. The Zeocin resistance gene was applied as a valuable reporter for mutant P AOX1 promoter activity, and we used an episomal plasmid vector to ensure a constant reporter gene dosage in the yeast host cells. This novel design enabled direct selection for colonies of recombinant cells with altered Zeocin tolerance levels originating solely from randomly introduced point mutations in the P AOX1 promoter DNA sequence. We demonstrate that this approach can be used to select for P AOX1 promoter variants with abolished glucose repression in large mutant libraries. We also selected P AOX1 promoter variants with elevated expression level under induced conditions. The properties of the selected P AOX1 promoter variants were confirmed by expressing luciferase as an alternative reporter gene. The tools developed here should be useful for effective screening, characterization, and improvement of any yeast promoters.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23841098 PMCID: PMC3690208 DOI: 10.1155/2013/926985
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Strains and vectors used in this study.
| Strain or plasmid | Descriptiona,b,c | Reference or source |
|---|---|---|
|
| ||
| DH5 | General cloning host. | BRL |
| ER2925 | Host used for cloning experiments involving methylation-sensitive restriction enzymes. | NEB |
|
| ||
| GS115 | Host used for all of the | Invitrogen |
| Vectors | ||
| pIB11 | Bacterial RK2-based expression vector harboring | [ |
| pGL3-control vector | Firefly luciferase reporter vector, ApR. | Promega |
| pBGP1 |
| [ |
| pPICZ A |
| Invitrogen |
| pPPE3 | pBGP1 derivative in which the three BspHI restriction sites are deleted including one situated in the | This study |
| pPPE8 | pPPE3 derivative in which a BspHI restriction enzyme site was inserted in the start of the zeocin-resistance gene by using site-directed mutagenesis with primer pair 4, ApR. | This study |
| pPPE10 | pPPE8 derivative in which the zeocin-resistance gene was substituted with the kanamycin-resistance gene from plasmid pIB11. The | This study |
| pPPE11 | pPPE10 derivative in which a NcoI restriction enzyme site was inserted in the start of the Alpha signal by using site-directed mutagenesis with primer pair 6, ApR, KmR, G418R. | This study |
| pPPE12 | pPPE11 derivative in which the zeocin-resistance gene was inserted as reporter for the modified | This study |
| pPPE17 | pPPE12 derivative in which the modified | This study |
| pIPA1 | pPICZ A derivative in which the BspHI restriction enzyme site in the | This study |
| pIPA4 | pIPA1 derivative in which an EcoRI restriction enzyme site is inserted directly upstream of the putative TATA-box in the | This study |
| pIPA5 | pIPA4 derivative in which a NheI restriction enzyme site is inserted downstream of the transcriptional start site in the | This study |
| pPPE20 | Similar to pPPE17 except for that the | This study |
| pPPE22 | Similar to pPPE17 except for that the | This study |
| pPPE35 | Similar to pPPE17 except for that the | This study |
| pPPE50 | Similar to pPPE20 except for that a KpnI restriction enzyme site is inserted in the | This study |
aAp: ampicillin; Km: kanamycin; Zc: Zeocin, G418: aminoglycoside antibiotic.
bSequences of the primer pairs are listed in Table 2.
cThe target region was subcloned and verified by sequencing for all of the site-directed mutagenesis applications. Also, all cloned regions amplified by PCR were verified by sequencing.
Primers used in genetic modifications.
| Primer pair number | Sequencea |
|---|---|
| 1 | 5′-TGTATCCGCTAATGAGACAAT-3′ and |
| 2 | 5′-GATTTTGGTAATGAGATTAT-3′ and |
| 3 | 5′-GGACGCATGTAATGAGATTATT-3′ and |
| 4 | 5′-AGGAACTAAA |
| 5 | 5′-TAATAA |
| 6 | 5′-ATTTCGAAA |
| 7 | 5′-TAATAA |
| 8 | 5′-TAATAA |
| 9 | 5′-AGCCTAACGTTAATGATCAAAATT-3′ and |
| 10 | 5′-AAAATTTAACTGTTC |
| 11 | 5′-TCATAATTGCGACT |
| 12 | 5′-TAATAA |
| 13 | 5′-TAATAA |
| 14 | 5′-ACCCGCTTTTT |
aThe restriction enzyme site is underlined.
Figure 1Physical map of the E. coli-P. pastoris shuttle plasmid pPPE17 and its derivatives. The restriction enzyme sites shown are unique. Abbreviations: P : P. pastoris AOX1 promoter; Zc : Zeocin resistance gene; AOX1 TT: P. pastoris AOX1 transcription termination region; P : yeast promoter TEF1; P : bacterial promoter EM7; Km : kanamycin resistance gene (confers resistance against kanamycin in bacteria and G418 in yeast); PARS1: P. pastoris autonomous replication sequence; pUC origin: bacterial replication sequence; Ap : ampicillin resistance gene (bla). DNA sequence of the 3′-part of the wild-type P promoter (base pairs 670 to 950) is displayed above the plasmid map. The promoter core region is shown in bold (see also text). The transcriptional start site (A) and the putative TATA-box (TATATAAA) are highlighted in grey. The BspHI (TCATGA) restriction enzyme site is written in bold and underlined and is deleted by the introduction of a point mutation (TATGA) in plasmids pPPE20 and pPPE50. GGATGA is mutated to the KpnI (GGTACC) restriction enzyme site in plasmids pPPE50. TAACCC is mutated to the EcoRI (GAATTC) restriction enzyme site in plasmids pPPE20 and pPPE50. CCAATT is mutated to the NheI (GCTAGC) restriction enzyme site in plasmid pPPE20 and pPPE50.
Figure 2DNA sequence of region between base pairs-159 to +41 (promoter core region and the about 90 base pairs region directly upstream of the promoter core region, the transcriptional start site is set as +1) of the wild-type P promoter and variants LC-1, LC-2, and LU-1 to LU-6. Mutations are shown in bold and underlined. Deletion mutations are indicated by short horizontal lines. The transcriptional start site (A) and the putative TATA-box (TATATAAA) are written in upper case and highlighted in grey. Mutations leading to restriction-enzyme-site insertions or deletions without affecting the promoter activity are written in grey. The KpnI (GGTACC), EcoRI (GAATTC), and NheI (GCTAGC) restriction enzyme sites are written in upper case and underlined. The relative Zeocin tolerance levels of the promoter variants compared to the wild-type promoter under repressed (wild-typeR) and induced (wild-typeI) growth conditions are shown.
Figure 3Relative luciferase activities under repressed growth conditions and during the glucose-depletion phase for the wild-type P. pastoris P promoter (black squares) and variants LC-2 (grey triangles) and LU-2 (black circles, dashed line) in plasmid pPPE35 expressed in P. pastoris GS115. Enzyme activities are shown in logarithmic scale. The values are the average of two biological replicas, and the error bars show the standard deviations. The activities are relative to the wild-type, for which the value at the first time point is arbitrarily set to 1.